FPR1 Antibody

What is FPR1 and why is it an important research target?

FPR1 (formyl peptide receptor 1) is a G-protein-coupled receptor primarily expressed in neutrophils, monocytes, and macrophages. It mediates critical immune responses including degranulation and chemotaxis when activated by formyl-peptide ligands derived from bacteria or mitochondria. The significance of FPR1 extends to both inflammatory conditions and cancer research, as it represents a potential therapeutic target for inflammation-related diseases exacerbated by bacterial infection and tissue damage. Additionally, FPR1 has been shown to be selectively expressed on highly malignant human glioma cells where it may contribute to tumor progression, highlighting its potential as a therapeutic target for malignant glioblastoma . Research targeting FPR1 through specific antibodies enables deeper understanding of immune cell regulation and potential therapeutic interventions.

What are the common alternative names for FPR1 in the scientific literature?

When conducting literature searches or discussing FPR1 with colleagues, researchers should be aware of its various nomenclature to ensure comprehensive research coverage. FPR1 may be referenced under several alternative designations including FMLP, fMLP Receptor, Fpr, fMet-Leu-Phe receptor, and N-formylpeptide chemoattractant receptor . The protein has a molecular weight of approximately 38.4 kilodaltons. Understanding these alternative designations is crucial when conducting comprehensive literature searches or when examining older publications where alternative terminology may have been used. When planning cross-species studies, researchers should note that based on gene homology, there are identifiable orthologs in yeast, monkey, mouse, and rat systems, though sequence conservation varies significantly between species .

What are the primary applications for FPR1 antibodies in research?

FPR1 antibodies serve multiple experimental applications in research settings. Common methodologies include:

The selection of the appropriate application depends on your specific research question. For comprehensive analysis, utilizing multiple complementary techniques is recommended to validate findings across different experimental platforms .

How do I select the appropriate FPR1 antibody for my specific experimental needs?

When selecting an FPR1 antibody for your research, consider these critical factors:

• Species reactivity: Determine which species your samples are derived from and ensure the antibody has documented reactivity. Common reactivities include human (Hu), mouse (Ms), and rat (Rt), with varying cross-reactivity profiles .

• Application compatibility: Verify the antibody has been validated for your specific application (WB, ELISA, IHC, FCM, etc.). Some antibodies perform well in certain applications but poorly in others due to epitope accessibility differences .

• Conjugation requirements: Determine whether you need an unconjugated antibody or one conjugated to a detection molecule (FITC, HRP, APC, etc.) based on your detection system .

• Clonality consideration: Monoclonal antibodies offer higher specificity but recognize single epitopes, while polyclonal antibodies recognize multiple epitopes but may have higher background. For membrane proteins like FPR1, monoclonals often provide cleaner results in applications like flow cytometry .

• Validation data: Review available experimental validation data including images, citations, and protocols to assess antibody performance in contexts similar to your planned experiments .

What methodological approaches are most effective for validating FPR1 antibody specificity?

Proper validation of FPR1 antibody specificity is crucial for producing reliable research outcomes. A comprehensive validation strategy should include:

• Positive and negative cell controls: Test the antibody on cell lines with known FPR1 expression profiles. Neutrophils, monocytes, and certain macrophage populations should demonstrate positive staining, while FPR1-negative cell populations should show minimal background .

• Genetic knockdown/knockout validation: Use cells with genetically reduced or eliminated FPR1 expression through CRISPR-Cas9, shRNA, or siRNA approaches. Signal reduction/elimination in these samples confirms specificity .

• Peptide competition assays: Pre-incubate the antibody with purified FPR1 peptide (corresponding to the immunogen) before application to samples. Signal reduction indicates specific binding .

• Cross-reactivity assessment: Test against other FPR family members (FPR2/ALX and FPR3) to ensure the antibody does not cross-react with these closely related proteins .

• Multi-antibody verification: Compare results from antibodies recognizing different epitopes on FPR1. Concordant results from multiple antibodies strengthen confidence in specificity .

• Functional validation: Assess whether the antibody functionally inhibits formyl peptide-induced responses in appropriate cellular assays, such as calcium signaling or CD11b up-regulation in neutrophils .

How can I optimize immunostaining protocols for detecting FPR1 in different tissue contexts?

Optimizing immunostaining for FPR1 requires careful consideration of its membrane protein nature and tissue-specific expression patterns:

• Fixation optimization: For FPR1, a GPCR with small extracellular domains, fixation significantly impacts epitope accessibility. Compare 4% paraformaldehyde (preserves structure but may mask epitopes) with milder fixatives like 2% paraformaldehyde or methanol for optimal epitope preservation .

• Antigen retrieval methods: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) should be systematically compared, as FPR1 epitopes respond differently to various retrieval conditions .

• Permeabilization considerations: For intracellular epitopes, compare detergent-based permeabilization methods (0.1-0.5% Triton X-100, 0.1-0.3% Saponin) to determine optimal conditions that maintain membrane integrity while allowing antibody access .

• Signal amplification strategies: For tissues with low FPR1 expression, implement tyramide signal amplification (TSA) or other amplification methods to enhance detection sensitivity while maintaining specificity .

• Background reduction: Pre-block with serum from the same species as the secondary antibody (5-10%), include 0.1-0.3% Tween-20 in wash buffers, and consider tissue-specific autofluorescence quenching methods for fluorescent applications .

• Counterstaining optimization: Select nuclear counterstains and companion markers carefully to avoid spectral overlap with your FPR1 detection system, particularly in multiplex immunofluorescence applications .

Developing a tissue-specific optimization matrix comparing these variables will yield the most consistent and reproducible results across different experimental contexts.

What are the key considerations when using FPR1 antibodies for studying neutrophil function?

Studying neutrophil function with FPR1 antibodies requires careful experimental design:

• Antibody neutralization potential: Select antibodies validated for functional inhibition of formyl peptide-induced neutrophil activation. For example, some antibodies like Fpro0165 demonstrate full neutralization of formyl peptide-mediated activation of primary human neutrophils, while others may bind without inhibiting function .

• Formyl peptide concentration optimization: The potency of inhibitory antibodies is often inversely related to formyl peptide concentration. Titrate formyl peptide ligands (fMLFF, fMIFL) to determine optimal working concentrations where antibody inhibition can be reliably measured .

• Readout selection: Choose appropriate functional readouts:

  • Calcium flux assays (rapid, sensitive)

  • CD11b upregulation (standard activation marker)

  • Chemotaxis assays (physiologically relevant)

  • Reactive oxygen species production

  • Degranulation markers

• Timing considerations: FPR1 activation kinetics are rapid, typically peaking within minutes. Establish detailed time courses for each readout to ensure measurements are taken at optimal time points .

• Control treatments: Include appropriate controls:

  • Isotype control antibodies at matching concentrations

  • Known FPR1 antagonists (e.g., cyclosporin H, Boc-MLF)

  • Alternative activation pathways (e.g., C5a, IL-8) to confirm specificity

• Species considerations: Be aware that most functional FPR1 antibodies show species-specific activity. For example, antibodies like Hy38-1 may show high potency against human FPR1 (IC50 of 34 nM) but significantly reduced activity against cynomolgus FPR1 .

What approaches can address the challenges of using antibodies against FPR1 as a GPCR membrane protein?

GPCRs like FPR1 present unique challenges for antibody-based research due to their complex membrane structure and small extracellular domains:

• Conformational epitope preservation: Traditional fixation methods may disrupt GPCR conformation. Consider:

  • Mild fixation protocols (0.5-2% paraformaldehyde, short durations)

  • Chemical crosslinking optimization

  • Native membrane preservation techniques during sample preparation

• Cell-based selection strategies: When developing or selecting antibodies, prefer those validated on intact cells rather than purified proteins, as this ensures recognition of the native conformation. Whole-cell immunization and screening approaches have proven successful for generating functional FPR1 antibodies like Hy38-1 .

• Detergent selection for solubilization: When preparing FPR1 for biochemical analysis:

  Detergent	Concentration	Benefits	Limitations
  DDM	0.1-1%	Preserves function	Micelle size may interfere
  Digitonin	0.5-1%	Gentle extraction	Expensive, variable purity
  CHAPS	0.5-1%	Maintains protein-protein interactions	Less efficient extraction
  Triton X-100	0.1-0.5%	Efficient extraction	May disrupt conformational epitopes

• Receptor internalization considerations: FPR1 rapidly internalizes upon ligand binding. For studies of cell-surface FPR1, consider:

  • Working at 4°C to inhibit internalization

  • Using fixation before ligand addition

  • Including trafficking inhibitors when appropriate

• Cross-reactivity challenges: Due to the high homology between FPR family members, prioritize antibodies specifically validated for distinguishing between FPR1, FPR2/ALX, and FPR3 .

How do I design experiments to assess FPR1 antibody cross-reactivity between human and non-human primate models?

Developing therapeutic antibodies often requires assessment of species cross-reactivity, particularly between human and non-human primate targets. For FPR1, this presents specific challenges:

• Sequence homology analysis: Begin by examining the sequence conservation between human and cynomolgus monkey FPR1, particularly in extracellular domains. Note that the amino acid sequence identity in the extracellular regions is approximately 75%, which is relatively low and complicates cross-reactivity .

• Cell-based screening systems: Establish parallel cell lines expressing either human or cynomolgus FPR1 with equivalent expression levels (confirmed by mRNA quantification and surface staining with non-discriminating tools). These paired cell lines provide the foundation for comparative binding and functional studies .

• Comparative binding assessment: Evaluate antibody binding to both human and cynomolgus FPR1 using flow cytometry with titrated antibody concentrations to generate complete binding curves. Calculate EC50 values and maximum binding levels to quantify differences in affinity and binding capacity .

• Cross-species functional inhibition comparison: Test antibodies in parallel functional assays using:

  • Calcium mobilization assays with human and cynomolgus FPR1-transfected cells

  • Primary neutrophil assays from both species measuring identical readouts (e.g., CD11b upregulation)

• Epitope mapping strategy: For antibodies showing differential activity between species, conduct systematic epitope mapping through:

  • Mutagenesis of divergent residues in extracellular loops

  • Creation of chimeric receptors swapping extracellular domains

  • Competition binding with peptides corresponding to extracellular regions

• Affinity maturation approach: For therapeutic antibody development, consider phage display-based affinity maturation targeting the specific epitopes that contribute to species cross-reactivity, as successfully demonstrated with the Hy38-1 antibody which was engineered to improve its weak cross-reactivity to cynomolgus FPR1 .

What methodological strategies can overcome the challenges of generating high-affinity antibodies against FPR1?

Generating high-affinity antibodies against GPCRs like FPR1 presents unique challenges due to their complex structure and limited extracellular domains. Effective strategies include:

• Immunization optimization: Rather than using purified proteins which may not maintain native conformation, immunize with:

  • Whole cells overexpressing FPR1 in multiple cell backgrounds (e.g., CHO-K1 and HEK293)

  • Alternating immunization with cells expressing FPR1 from different species to favor conserved epitopes

  • RIMMS (repetitive immunization at multiple sites) approach which has yielded successful antibodies like Hy38-1

• Screening strategy refinement: Implement multi-tier screening cascades:

  • Initial selection for binding specificity to FPR1-expressing vs. parental cells

  • Secondary functional screens in calcium mobilization assays

  • Tertiary validation in physiologically relevant systems (primary neutrophils)

• Affinity maturation approaches: For antibodies with desired specificity but suboptimal affinity or cross-reactivity:

  • Phage display technology using cells as the sole source of FPR1 antigen

  • CDR (complementarity-determining region) mutagenesis focusing on the VH CDR3 region which often mediates GPCR binding

  • Directed evolution with stringent selection conditions to identify higher-affinity variants

• Structural considerations: The crystal structure of anti-FPR1 antibody Fpro0165 revealed a long, protruding VH CDR3 of 24 amino acids that appears critical for its binding mode. This suggests that antibodies with extended CDR3 loops may be particularly effective against GPCRs with small extracellular domains .

• Epitope focusing: Target the most accessible extracellular epitopes of FPR1:

  • N-terminal domain (most exposed)

  • ECL2 (extracellular loop 2, typically the largest)

  • Conformational epitopes spanning multiple extracellular regions

Future Directions in FPR1 Antibody Research

The development and application of FPR1 antibodies continue to evolve, with several important trends emerging:

• Therapeutic applications: As FPR1's role in inflammatory diseases and cancer becomes better understood, the development of therapeutic antibodies is gaining momentum. Current challenges include optimizing species cross-reactivity for preclinical studies and enhancing functional inhibition potency .

• Advanced imaging applications: New super-resolution microscopy techniques are enabling detailed studies of FPR1 localization, trafficking, and signaling complex formation, requiring antibodies specifically validated for these applications.

• Conformation-specific antibodies: Future research will likely focus on developing antibodies that recognize specific conformational states of FPR1 (active vs. inactive), allowing more nuanced studies of receptor activation and signaling.

• Multiparametric analysis tools: The integration of FPR1 antibodies into mass cytometry, multiplexed imaging, and other high-dimensional analytical platforms will provide deeper insights into its role in complex cellular networks.

• FPR family differential targeting: Development of antibody panels that can precisely distinguish between FPR1, FPR2/ALX, and FPR3 will be crucial for understanding the distinct roles of these related receptors in immunity and disease.